nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2015 | Original Article – Clinical Oncology

Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation

verfasst von: A. Rockstroh, H. K. Al-Ali, T. Lange, W. Pönisch, R. Krahl, M. Cross, G. Behre, D. Niederwieser, C. Pfrepper

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Allogeneic haematopoietic stem cell transplantation (HSCT) is a proven treatment for patients with haematological malignancies. In this retrospective analysis, the impact of donor matching on outcome of unrelated HSCT was analysed in patients transplanted at the University of Leipzig.

Methods

From 2000 to 2009, 206 patients were transplanted from unrelated donors, of which 51 were mismatched (39 in 1 and 12 in ≥2 HLA-antigens), using peripheral blood or bone marrow grafts after total body irradiation and cyclophosphamide or busulfan and cyclophosphamide preparative regimens in combination with ATG. For graft-versus-host disease (GvHD) prophylaxis cyclosporine and MTX were administered.

Results

After a median follow-up of 49 months, outcome at 5 years in recipients of HLA-identical grafts was comparable to that of patients transplanted from HLA-incompatible donors with an overall survival (OS) of 52 % (95 % CI 43–61) versus 48 % (95 % CI 34–63), respectively (p = 0.48). Results were also comparable for event-free survival at 5 years [47 % (95 % CI 38–56) vs. 39 % (95 % CI 25–54); p = 0.44], relapse incidence (RI) [29 % (95 % CI 20–38) vs. 41 (95 % CI 25–57); p = 0.22] and non-relapse mortality [24 % (95 % CI 16–33) vs. 20 % (95 % CI 8–33); p = 0.84] in the matched versus mismatched groups. Incidence of acute and chronic GvHD was similar in both groups. Advanced disease (p = 0.02) and low-resolution typing (p = 0.04) are risk factors for OS and RI in univariate and multivariate analysis.

Conclusions

Donors with one antigen mismatch are an acceptable option for patients with malignant disease for whom no fully matched donor is available.

Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al (1989) Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320(4):197–204CrossRefPubMed

Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23(15):3447–3454CrossRefPubMed

Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E et al (2007) Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transpl 13(1):82–89CrossRef

Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE (2001) Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 97(10):2957–2961CrossRefPubMed

Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE (2003) Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102(5):1915–1919CrossRefPubMed

Basara N, Baurmann H, Kolbe K, Yaman A, Labopin M, Burchardt A et al (2005) Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transpl 35(10):1011–1018CrossRef

Beatty P, Dahlberg S, Mickelson EM, Nisperos B, Opelz G, Martin P et al (1988) Probability of finding HLA-matched unrelated marrow donors. Transplantation 45:714–718CrossRefPubMed

Beatty PG, Anasetti C, Hansen JA, Longton GM, Sanders JE, Martin PJ et al (1993) Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 81(1):249–253PubMed

Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP et al (1991) Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 78:838–843PubMed

Feinstein LC, Sandmaier BM, Hegenbart U, McSweeney PA, Maloney DG, Gooley TA et al (2003) Non-myeloablative allogafting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 120:281–288CrossRefPubMed

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509CrossRef

Finke JÃ, Schmoor C, Lang H, Potthoff K, Bertz H (2003) Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 21(3):506–513CrossRefPubMed

Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M et al (2004) Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104(7):1923–1930CrossRefPubMed

Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al (1991) Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325(23):1601–1607CrossRefPubMed

Gooley TA1, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695–706CrossRefPubMed

Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101PubMedCentralCrossRefPubMed

Gratwohl A, Hermans J, Goldman J, Arcese W, Carreras E, Devergie A et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352:1087–1092CrossRefPubMed

Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, De Witte T et al (2009) Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer 115(20):4715–4726CrossRefPubMed

Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J et al (2011) Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 29(15):1980–1986CrossRefPubMed

Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16(3):1441–1454CrossRef

Greinix HT, Faé I, Schneider B, Rosenmayr A, Mitterschiffthaler A, Pelzmann B et al (2005) Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transpl 35(1):57–62CrossRef

Kanda J, Saji H, Fukuda T, Kobayashi T, Miyamura K, Eto T et al (2012) Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood 119(10):2409–2416CrossRefPubMed

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al (1993) Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 328:593–602CrossRefPubMed

Kroeger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G et al (2009) HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transpl 15(4):454–462CrossRef

Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Durken M et al (2001) Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 80(4):209–215CrossRefPubMed

la Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E et al (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96(3):441–449PubMedCentralCrossRefPubMed

Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344(24):1815–1822CrossRefPubMed

Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110(13):4576–4583CrossRefPubMed

Ljungman P, Urbano Ispizua A, Cavazzani-Calvo M, Demirer T, Dini G, Einsele H et al (2006) Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transpl 37:439–449CrossRef

Loiseau P, Busson M, Balere ML, Dormoy A, Bignon JD, Gagne K et al (2007) HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transpl 13(8):965–974CrossRef

Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065–3073CrossRefPubMed

Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50(3):163–170PubMed

Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al (2003) HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102(6):2021–2030CrossRefPubMed

McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina A-J, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 1(97):3390–3400CrossRef

Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K et al (2002) The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99(11):4200–4206CrossRefPubMed

Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS et al (1995) The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86(3):1228–1234PubMed

National Marrow Donor Program (1992) Donor center manual of operations. Minneapolis, Chapter 6 (p 11)

Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier B et al (2003) Low-dose total body irradiation (TBI) and fludarabine follwed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4):1620–1629CrossRefPubMed

Petersdorf EW, Kollman C, Hurley CK, Dupont B, Nademanee A, Begovich AB et al (2001a) Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98(10):2922–2929CrossRefPubMed

Petersdorf EW, Hansen JA, Martin PJ, Woolfrey A, Malkki M, Gooley T et al (2001b) Major-histocompatibility-complex class I alleles and antigens in hematopoetic-cell transplantation. N Engl J Med 345(25):1794–1800CrossRefPubMed

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transpl 15(6):825–828

Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H et al (1998) Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 339(17):1177–1185CrossRefPubMed

Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al (2012) The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 119(11):2657–2664PubMedCentralCrossRefPubMed

Shaw BE, Madrigal JA, Potter M (2001) Improving the outcome of unrelated donor stem cell transplantation by molecular matching. Blood Rev 15(4):167–174CrossRefPubMed

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 seattle patients. Am J Med 69:204–217CrossRefPubMed

Slavin MA1, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 171(6):1545–1552CrossRefPubMed

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919PubMedCentralCrossRefPubMed

Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al (2007) Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25(27):4246–4254CrossRefPubMed

Storb R, Deeg HJ, Pepe M, Appelbaum FR, Anasetti C, Beatty P et al (1989) Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73:1729–1734PubMed

Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al (2008) Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transpl 14(7):748–758CrossRef

Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M et al (2011) HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transpl 17(6):885–892CrossRef

Titel: Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation
verfasst von: A. Rockstroh
H. K. Al-Ali
T. Lange
W. Pönisch
R. Krahl
M. Cross
G. Behre
D. Niederwieser
C. Pfrepper
Publikationsdatum: 01.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-2003-5

Springer Medizin

Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation